Mesoblast (ASX:MSB) Presentation, FNN Investor Event, August 2018, Sydney

Company Presentations

Mesoblast Limited (ASX:MSB) Head of Business Development and Licensing, David Oxley, presents details about the company's Phase 3 trials, its agreement with Tasly China and the near-term potential of stem cell medicines at FNN's Investor Event.

Key points:

  • Disruptive cellular medicine technology
  • Investment objective and strategy
  • Phase 3 trial in patients with Advanced Heart Failure
  • Acute Graft Versus Host Disease
  • Strategic partnership for cardiovascular franchise in China
  • Key portfolio metrics
  • Capital management
  • Corporare milestones

For more, watch Head of Business Development and Licensing, David Oxley, present